1107 related articles for article (PubMed ID: 12885813)
1. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
2. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
3. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
4. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
5. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
6. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
[TBL] [Abstract][Full Text] [Related]
7. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
[TBL] [Abstract][Full Text] [Related]
9. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
[TBL] [Abstract][Full Text] [Related]
10. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
Lee SS; Lee JH; Lee JH; Kim DY; Kim SH; Lim SN; Lee YS; Seol M; Ryu SG; Kang YA; Jang S; Park CJ; Chi HS; Yun SC; Lee KH
Leuk Res; 2009 Apr; 33(4):511-7. PubMed ID: 18819710
[TBL] [Abstract][Full Text] [Related]
11. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Ryu SG; Jang S; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
Leuk Res; 2006 Feb; 30(2):204-10. PubMed ID: 16055185
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Feldman EJ; Brandwein J; Stone R; Kalaycio M; Moore J; O'Connor J; Wedel N; Roboz GJ; Miller C; Chopra R; Jurcic JC; Brown R; Ehmann WC; Schulman P; Frankel SR; De Angelo D; Scheinberg D
J Clin Oncol; 2005 Jun; 23(18):4110-6. PubMed ID: 15961759
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
[TBL] [Abstract][Full Text] [Related]
15. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
[TBL] [Abstract][Full Text] [Related]
16. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
[TBL] [Abstract][Full Text] [Related]
17. [Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Reinhardt D; Hempel G; Fleischhack G; Schulz A; Boos J; Creutzig U
Klin Padiatr; 2002; 214(4):188-94. PubMed ID: 12165900
[TBL] [Abstract][Full Text] [Related]
18. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia.
Harousseau JL; Milpied N; Brière J; Desablens B; Ghandour C
Nouv Rev Fr Hematol (1978); 1990; 32(4):227-30. PubMed ID: 2290708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
